Fig. 6: The synergy between dexamethasone and kinase inhibitors. | npj Precision Oncology

Fig. 6: The synergy between dexamethasone and kinase inhibitors.

From: The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia

Fig. 6

a Using the same 500-gene signature and drug synergy data from the DrugComb database, a deep learning binary classification model was developed to predict synergy between dexamethasone and other inhibitors. b Model performance was tested using 108 test samples. c Confusion matrix showing the model’s performance using 108 test samples. d In silico synergy prediction between dexamethasone and 1454 kinase inhibitors using the deep learning model. e In vitro synergy measurement between dexamethasone and kinase inhibitors in TANOUE cells using Cell Titer Glo after 48 h of incubation with drug combinations. The figure shows representative kinase inhibitors. f In vitro synergy measurement between dexamethasone and β-catenin inhibitors in TANOUE cells using Cell Titer Glo after 48 h of incubation with drug combinations.

Back to article page